For example, in the experimental rat model of hypertension and NO dysfunction with deoxycorticosterone acetate (DOCA)-salt and nitric oxide synthase inhibitor Nω-nitro-l-arginine (NOARG), a prototype ETA antagonist treatment produced a major protection against hypertensive nephron damage evidently mediated via NF-kB and ET-1/ETA pathways (Kimura et al., 2012). This evidence concerns the gene EDNRA and hypertensive disorder.